Johnson & Johnson Has an Impressive Growth Story, Says Jim Cramer

Johnson & Johnson's earnings reveal just how impressive growth is at the big pharma company, according to Jim Cramer.
Author:
Publish date:

Johnson & Johnson's   (JNJ) - Get Report  earnings reveal just how impressive growth is at the big pharma company, according to TheStreet's Jim Cramer. He points to J&J's anti-cancer drug franchise, strong balance sheet, a share gains in consumer products as reasons to like the stock. Cramer also likes the improvement in J&J's medical devices division.